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Population mean GFR is lower in older age, but it is unknown whether healthy ageing is 
associated with preserved rather than lower GFR in some people. In this paper, the authors 
defined persons without major chronic disease and risk factors for chronic kidney disease as 
healthy and studied the cross-sectional association of being healthy with iohexol clearance in 
three European population-based cohorts. The mean and the 97.5th percentile of the GFR 
distribution were higher in healthy than in unhealthy old persons, but lower than in healthy 
middle-aged people. The GFR-age association was more negative in women than in men. 
These results suggest that although being healthy is associated with higher GFR in old age, 







The prevalence of low glomerular filtration rate (GFR) is higher at older age. Although 
previous studies have indicated that some persons age without loss of GFR, it is unknown 
whether healthy ageing is associated with preserved rather than lower GFR. We investigated 
the cross-sectional association between measured GFR, age and health in persons aged 
between 50 and 97 years in the general population. 
Methods 
This study is a meta-analysis of 4209 iohexol clearance measurements in 2885 Europeans in a 
collaboration between the Berlin Initiative Study, the Age, Gene/Environment Susceptibility - 
Kidney Study and the Renal Iohexol Clearance Survey. We defined a healthy person as 
someone without major chronic disease and risk factors for chronic kidney disease and all 
others as unhealthy. We used a generalized additive model to study the GFR distribution by 
age according to health status. 
Results 
There were 935 (22%) GFR measurements in healthy and 3274 (78%) in unhealthy persons. 
The mean (95% confidence interval) GFR in healthy vs. unhealthy men was lower at older 
age by -0.72 (-0.96 to -0.48) vs. -1.03 (-1.25 to -0.80), and for women by -0.92 (-1.14 to -
0.70) vs. -1.22 (-1.43 to -1.02) mL/min/1.73 m2/year. For healthy and unhealthy persons of 
both sexes, both the 97.5th and 2.5th GFR percentile exhibited a negative linear association 
with age. 
Conclusion 
Healthy ageing is associated with a higher mean GFR than unhealthy ageing, but both the 
mean and 97.5 percentiles of the GFR distribution are lower in old healthy persons than in 
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middle-aged healthy persons. This suggests that healthy ageing is not associated with 







The Global Burden of Disease Study has found that ageing was responsible for 43% of the 
increased loss of disability-adjusted life-years caused by chronic kidney disease (CKD) 
between 1990 and 2016.1 Improved survival for the oldest age groups combined with an 
almost exponential increase in CKD prevalence with age indicate that this trend will probably 
continue.2  
Because of the age-related reduction in population mean GFR, there is an ongoing debate 
about whether the CKD definition should be changed to incorporate age-varying GFR 
thresholds.3, 4 However, it is not known whether lower mean GFR in older people is caused by 
natural senescence or by diseases associated with lower GFR in the elderly. Some 
longitudinal studies have found a preserved or improved rather than lower GFR in a 
significant proportion of ageing persons.5 Although this suggests that good health may 
prevent age-related GFR decline, studies of kidney biopsies from living kidney donors 
demonstrate that a reduction in the number of nephrons occurs from a young age even in the 
absence of disease.6  
Our current knowledge about ageing and GFR in the general population mainly comes from 
cross-sectional studies performed decades ago, which have been summarized in a detailed 
review by Delanaye et al.7 Few, if any, of these studies were population-based, and the 
number of participants older than 65 years was very small.7 Because the prevalence of chronic 
disease is higher at older age, we have little knowledge about the effects of natural ageing vs. 
disease on GFR in the last decades of life. Although there are some large population-based 
studies based on GFR estimated from serum creatinine, 8-15 this approach is problematic in 
older people because of confounding by sarcopenia and other non-GFR related factors.16-20 
We performed a meta-analysis of individual participant data from four population-based 
studies in three European cohorts where GFR had been measured using plasma iohexol 
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clearance in persons aged between 50 and 97 years. Our aims were to study the association of 
GFR with age in healthy persons and predict reference intervals for GFR in healthy ageing 
across the studied age range. As it would not be possible to perform a population-based study 
with a high number of truly healthy individuals in the oldest age-groups, we designed the 
study to use a generalized additive regression model to adjust for the association of 
comorbidity and risk factors with GFR and to predict the distribution of GFR in 







This cross-sectional investigation was a collaboration between population-based studies in 
Europe that measured GFR using exogenous filtration markers. Information about eligible 
studies was obtained from the European Kidney Function Consortium and from a search of 
literature databases. Three eligible cohorts were identified: The Renal Iohexol Clearance 
Survey in Tromsø 6 (RENIS-T6) (n=1632),21 the Berlin Initiative Study (BIS) (n=610)22 and 
the Age, Gene/Environment Susceptibility (AGES) - Kidney Study (n=819) (Figure 1).23 The 
RENIS cohort included a repeated GFR measurement in the RENIS Follow-up Study 
(RENIS-FU) after a mean follow-up of 5.6 years (n=1329).24 The examinations in RENIS-T6 
and RENIS-FU were both included in the present investigation. 
The RENIS cohort included participants between 50 and 63 years of age at baseline from the 
sixth wave of a series of population surveys in the municipality of Tromsø in Northern 
Norway.21 The response rate in the sixth Tromsø Study was 74% for persons eligible for 
RENIS.25 BIS recruited persons from the German healthcare fund ‘‘Allgemeine 
Ortskrankenkasse Nordost’’ in Berlin. The response rate for the total BIS cohort was 8.1%. 
AGES-Kidney is a substudy of the AGES-II-Reykjavik Study, which was a follow-up of the 
population-based Reykjavik Study in Iceland.23 The response rate in the AGES-II-Reykjavik 
Study was 71% 26 and for those eligible for AGES-Kidney 65%.23  
The inclusion criteria for the three cohorts were similar, except that AGES-Kidney excluded 
individuals receiving active cancer treatment, and BIS excluded persons that required nursing 
care during daytime and nighttime. RENIS excluded persons with self-reported diabetes, 
cardiovascular disease or kidney disease at baseline in RENIS-T6, but diabetes diagnosed by 
HbA1c ≥ 6.5% (≥ 48 mmol/mol) at baseline and incident cases during follow-up were 
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included.21 22 23 Persons receiving renal replacement therapy were excluded from all three 
cohorts. 
The people invited to AGES-Kidney and RENIS were random samples of the general 
population, and those invited to BIS a random sample from the ‘‘Allgemeine 
Ortskrankenkasse Nordost’’, which provides insurance coverage to almost 50% of persons 
older than 70 years in Berlin.22 Although participation was voluntary, the three cohorts of 
examined persons were all representative of their source populations. The RENIS cohort has 
been found similar to all eligible patients in the sixth Tromsø Study with respect to key 
variables.27 The mean estimated GFR, calculated using the MDRD equation, was 89.3 vs. 
90.6 ml/min/1.73 m2 for women, and 93.1 vs. 93.2 ml/min/1.73 m2 for men in RENIS and the 
Tromsø Study, respectively.  
The prevalence of the most important chronic diseases in BIS was similar to that of all 
persons older than 70 years in the “Allgemeine Ortskrankenkasse Nordost”.28 Also, the 
prevalence of diabetes,29 myocardial infarction,30 angina pectoris,30 stroke31 and cancer32 were 
of similar order of magnitude as in other German studies of chronic diseases in older adults.  
The participants in AGES-Kidney were younger, had lower systolic blood pressure, and were 
less likely to be current smokers or have cardiovascular disease or diabetes than participants 
in AGES-II-Reykjavik who were not included.23 The mean estimated GFR was 65.7 vs. 64.1 
mL/min/1.73 m2 among those who participated and those who did not.23 More detailed 
information about the cohorts can be found in previous publications.21-24 
Technically unsuccessful measurements were excluded from the investigations (RENIS-T6, 
n=5; RENIS-FU, n=5; AGES-Kidney n=14; BIS n=40) (Figure 1).21, 23, 24, 33 
This study was approved by the ethical review boards of the three respective investigations. 





Data on morbidity, smoking habits and medication use were obtained through questionnaires 
in all three cohorts. The use of individual classes of antihypertensive medications was 
registered in the following dichotomous variables: beta blockers, angiotensin converting 
enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blockers, loop diuretics, 
thiazide diuretics, mineralocorticoid receptor antagonists, other diuretics and other 
antihypertensive drugs, including alpha blockers. The use of lipid-lowering medications, 
antidiabetic drugs and cardiac glycosides (digoxin/digitoxin) was also registered. Smokers 
were categorized as current, previous or never.  
Definitions 
Diabetes was defined as either self-reported diabetes, use of anti-diabetic medication or 
HbA1c ≥ 6.5% (≥ 48 mmol/mol). 
Details about urinary creatinine and albumin measurements in all three cohorts have been 
given previously.23, 28, 34 The urinary albumin-to-creatinine ratio (ACR) was classified in the 
categories <10 mg/g, ≥ 10 and < 30 mg/g, and ≥ 30 mg/g, corresponding to the categories 
optimal, high normal and high/very high/nephrotic.35  
In RENIS and AGES-Kidney, blood pressure (BP) was measured as described previously,23, 36  
and in BIS, according to the ESC/ESH recommendations.37 Subjects with an office systolic 
BP ≥ 140 mm Hg, diastolic BP ≥ 90 mm Hg, or those who were on antihypertensive 
medications were categorized as having hypertension according to the ESC/ESH guidelines.37 
GFR measurements 
GFR was measured as plasma iohexol clearance in all three cohorts. Multiple-sample 
protocols were used in AGES-Kidney and BIS, and a single-sample protocol in RENIS. 
Details of the GFR measurement methods, including an investigation of agreement between 
the multiple- and single-sample protocols, have been previously reported.38 Substantial 
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agreement between the methods was found. Iohexol concentration was measured with high-
performance liquid chromatography in all three cohorts.38 The iohexol assays of the three 
studies were calibrated by reanalyzing thawed samples in the laboratory of the Department of 
Medical Biochemistry, University Hospital of North Norway (UNN), Tromsø, Norway. The 
results of the calibration have been reported previously.38 No calibration was found to be 
necessary for the BIS and RENIS samples, but the following equation was used to calibrate 
the AGES-Kidney results to the UNN laboratory: log(iohexolUNN)=-0.091+1.025 x 
log(iohexolAGES).38 This calibration resulted in a mean difference in GFR of only 0.87 
mL/min from the original results. 
GFR was indexed to 1.73 m2 body surface area. Body surface area was estimated using the 
equation developed by Dubois and Dubois.39  
Serum creatinine was analyzed using the same isotope dilution mass spectrometry-traceable 
enzymatic assay (CREA Plus, Roche Diagnostics, Mannheim, Germany) in all three 
cohorts.33, 36, 40 Estimated GFR was calculated from serum creatinine (eGFRcrea) using the 
Chronic Kidney Disease Epidemiology Collaboration equation.41 
Statistical methods 
Characteristics of the study participants were provided at the time of the GFR measurements, 
i.e. characteristics for the RENIS cohort was reported for both the baseline (RENIS-T6) and 
the follow-up (RENIS-FU) examination. Quantile regression was used for testing the 
unadjusted difference in median GFR across health status categories. 
“Health status” was defined as a dichotomous variable where a healthy person was defined as 
a person with no history of myocardial infarction, angina pectoris, coronary revascularization 
procedures, stroke, cancer, diabetes, hypertension, current smoking, or use of lipid-lowering 
medication or cardiac glycosides; body mass index (BMI) <30 kg/m2 and ACR < 30 mg/g. 
Because information about heart failure was not available in BIS and RENIS, it was not 
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included in the definition. However, most persons with heart failure caused by coronary heart 
disease would have been classified as unhealthy and medications commonly used for heart 
failure such as angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, 
beta-blockers, loop diuretics and mineralocorticoid receptor blockers were classified as 
antihypertensive drugs that would also have caused a participant to be categorized as 
unhealthy. Additionally, we included cardiac glycosides as another indicator of heart failure. 
This investigation was designed as a meta-analysis with individual participant data using a 
one-stage statistical analysis.42 The associations between GFR indexed for body surface area 
and age, sex, health status and cohort membership were explored in generalized additive 
regression models for location, scale and shape (GAMLSS) using the gamV procedure from 
the mgcViz-package in R.43, 44 GAMLSS is a new regression method suitable for modeling 
the age-dependent distribution of variables. A detailed explanation of the method can be 
found in the Supplemental Material. In brief, the mean and standard deviation (SD) of the 
GFR distribution are modeled as separate functions of the independent variables in the same 
regression model. These functions may be linear or non-linear. In addition to investigating the 
association of the independent variables with the mean of the GFR distribution as in ordinary 
regression methods, GAMLSS makes it possible to investigate their association with the SD 
of the distribution. This means that the association of any percentile of the GFR distribution 
across age can be studied instead of focusing only on the mean, similar to quantile regression.  
We analyzed the associations between GFR indexed for body surface area as the dependent 
variable and age, sex and health status as independent variables. We adjusted for the 
correlation between the first (RENIS-T6) and second (RENIS-FU) GFR measurement for the 
same individual in the RENIS cohort by including a random intercept for each participant in 
all models. Adjustment for cohort effects were made by including random coefficients for 
cohort membership and for the interaction between cohort membership and other independent 
variables. We assumed the same cohort effects for both rounds (RENIS-T6 and RENIS-FU) 
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of RENIS. The variance-covariance structure of the random effects was assumed to be 
independent in all models. The GFR-age association was defined as the difference in mean 
GFR per one year older age and is represented by the coefficient for the age-variable in the 
regression model. A negative GFR-age association signifies a lower population mean GFR by 
older age. The regression coefficient for the interaction between age and health status 
represents the association between health status and the GFR-age association. 
The Akaike Information Criterion (AIC) was used to compare the fit of different regression 
models.45 This criterion scores the models for fit to the data, but penalizes the score for the 
number of independent variables and complexity of the model. A lower AIC indicates a better 
fit. 
We first analyzed both the mean and the SD of the GFR distribution as functions of the main 
effects of age, sex and the health status variable. We also included the interaction between age 
and health status and a random sex-specific effect for cohort membership to adjust for 
possible differences in GFR distribution between the cohorts.  
In this model, statistically significant main effects of all the independent variables and the 
age-health status interaction were found for the mean of GFR (p<0.05). The cohort random 
effect was statistically significant for men, but not for women. This means that there is 
variation in the GFR level between the cohorts for men, but not for women. For the SD of 
GFR, there was no main effect of sex and no sex-specific cohort random effect (p ≥ 0.05). 
Accordingly, in the SD part of the model, the sex-specific cohort random effect was removed 
and a common cohort random effect for both sexes (p<0.05) was retained. The AIC for this 
model was 33380.43. 
To investigate the possibility of different associations between age and GFR distributions 
across the cohorts, we included random effects for the interaction between age and cohort in 
the functions for both the mean and the SD of GFR. The effect was statistically significant for 
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the mean, but not for the SD. This means that the GFR-age associations may differ between 
the cohorts, and adding this effect to the function for the mean of the model improved the fit 
(AIC=33306.61).  
Next, we tested interactions between age and sex, and health status and sex, for both the mean 
and SD in this model. Only the interaction between age and sex for the mean was statistically 
significant (p=0.005). This interaction also improved the fit (AIC=33302.43) and was 
included in the model. 
Possible non-linear effects of age were tested by adding smooth terms for the interaction 
between age and health status, and age and sex in separate models. This was done for both the 
mean and SD of GFR, but model fit was no better for these models than for the model without 
non-linear terms (AIC=33302.98 for the interaction between age and health status; 
AIC=33304.35 for age and sex). In a separate model, we also tested the effect of the three-
way interaction between age, sex and health status on the GFR mean, which was not 
statistically significant (p=0.34).  
The final model was used to predict and plot the 2.5th, median and 97.5th percentiles for the 
GFR distribution for individuals aged 50 to 95 years.46 We predicted the percentiles 
separately for men and women by health status. The random cohort effects in the model were 
set at zero in these predictions, which means that the predictions represent an average between 
the three cohorts. 
We used R version 3.5.1 (2018-07-02) (https://www.r-project.org/). Statistical significance 






The combined RENIS, BIS and AGES-Kidney cohorts comprise 4326 GFR measurements in 
3002 persons. Of these, 4209 (97%) observations in 2885 persons had complete datasets 
without missing data (Table S1) (Figure 1). Observations with missing data were omitted 
from the study population because multiple imputation methods for generalized additive 
regression models are not available. 
Baseline characteristics of the study population are shown in Table 1. RENIS-T6 and RENIS-
FU combined covered the age range 50 to 70 years, and the age ranges for BIS and AGES-
Kidney were 70 to 97, and 74 to 93 years, respectively. The differences between the cohorts 
shown in Table 1 reflect the variation in age and in inclusion criteria. AGES-Kidney and BIS 
are similar, except for higher prevalence of diabetes and ACR>=30 mg/g in BIS than in 
AGES-Kidney. The number of persons with BMI < 20 kg/m2 was 26 (1.6 %) in RENIS-T6,  
31 (2.3 %) in RENIS-FU, 4 (0.7 %) in BIS and 15 (2.1 %) in AGES-Kidney.   
A total of 513 (32%), 360 (27%), 18 (3%), and 44 (6%) participants were categorized as 
healthy in RENIS-T6, RENIS-FU, BIS and AGES-Kidney, respectively (Table 2). Baseline 
characteristics according to health status are shown in Table S2. A scatterplot of all the GFR 
measurements vs. age according to health status is presented in Figure 2. 
Table 2 shows the observed median, the 2.5th and 97.5 percentiles for GFR according to the 
health status variable for each of the cohorts. In BIS and AGES-Kidney, there was a 
statistically significant higher GFR for healthy vs. unhealthy persons (P<0.05), but not in 
RENIS-T6 or RENIS-FU.  
Using GAMLSS regression, we analyzed the mean and the SD of the GFR distribution as 
functions of age, sex, cohort and the health status variable (Table 3 and Table S3). The 
intercept of the model corresponds to the GFR-estimate for an unhealthy 50-year-old woman 
(Table 3). Being healthy was associated with a slightly lower mean GFR of 3.25 mL/min/1.73 
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m2 at age 50 years, but with a markedly higher GFR-age association of 0.30 mL/min/1.73 m2 
per year, as represented by the coefficient for the interaction between age and health status in 
Table 3 (p<0.001). Consequently, GFR was higher for healthy than for unhealthy people at all 
ages above 61 years (Figure 3). The GFR-age association was less negative for men than for 
women, being respectively -0.72 (95% CI -0.96 to -0.48) vs. -0.92 (95% CI -1.14 to -0.70) 
mL/min/1.73 m2 per year for healthy, and -1.03 (95% CI -1.25 to -0.80) vs. -1.22 (95% CI -
1.43 to -1.02)  mL/min/1.73 m2 per year for unhealthy persons (p=0.005 for the interaction 
between sex and the GFR-age association). The difference in GFR-age association between 
men and women was also observed when we stratified by age younger or older than 70 years 
(Figure S2), and by cohort, although this was not statistically significant (0.12, 0.12 and 0.16 
mL/min/1.73 m2 per year in RENIS, AGES-Kidney and BIS, respectively). 
There was no statistically significant association between the SD of the GFR distribution and 
older age (Table 3). This means that although mean GFR was lower at higher age, the 
variation in GFR at any given age for a given health status was more or less the same. 
However, healthy persons had a 19 % lower SD of their GFR distribution than the unhealthy 
(p<0.001), indicating that GFR varies less in healthy than in the unhealthy persons (Table 3).  
The random effects in the model demonstrate that there were differences between the cohorts 
with regard to the association between GFR and male sex, in the GFR-age association across 
age and in the SD of the GFR distribution (p<0.05) (Table S3). Because we had only three 
different cohorts, which may be considered few for the estimation of random effects, we 
replaced the random cohort effects with fixed effects and reanalyzed the model. The point 
estimates of the fixed effects model were very similar to the random effects model (Table S4).  
We repeated the analyses of the model shown in Table 3 with non-indexed GFR, measured in 
mL/min, as the dependent variable and height and weight added as independent variables. The 
effect of being healthy on the GFR-age association was very similar to that in the primary 
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analysis (0.32 (95% CI 0.20 to 0.45) vs. 0.30 (95% CI 0.18 to 0.43) mL/min/1.73 m2 per year; 
Table 3).  
Results of stratified analyses according to sex and age using the final model can be found in 
Supplemental Figure S2. The GFR-age association for healthy persons was consistently lower 
than zero in all the subgroups (p<0.05). The confidence interval for healthy persons over 70 
years of age was wide due to the small sample size in this category. 
The predicted median and 95% reference intervals for GFR in a healthy person based on the 
final GAMLSS model (Table 3) have been plotted against age for men and women in Figure 
3. The group defined as unhealthy is shown in gray for comparison. In healthy persons, the 60 
ml/min/1.73 m2  threshold intersects the 2.5th percentile at age 67.1 years for women and 70.8 
years for men (Figure 3). Table 4 presents predicted median GFR values and 95% reference 
ranges for five-year intervals in healthy men and women. Predicted 10th, 25th, 75th and 90th 
percentiles of the GFR distribution can be found in Table S5. 
The final GAMLSS-model in Table 3 was reanalyzed using eGFRcrea as the dependent 
variable instead of iohexol clearance (Table S6). The predicted median and 95% reference 
interval for eGFRcrea in a healthy person are compared to iohexol-clearance in Figure 4. 
Contrary to iohexol clearance, there was no sex-difference in the eGFRcrea-age association. 
Also, the SD of the eGFRcrea distribution demonstrated an increase with both age and female 
sex which was not seen with iohexol clearance. However, the eGFRcrea-age association was 






We found a negative linear association between population mean GFR and older age, even in 
persons defined as healthy by a set of very stringent criteria. The point estimate for the GFR-
age association in healthy persons was -0.72 and -0.92 mL/min/1.73 m2 per year in men and 
women, respectively. Previous cross-sectional estimates of the GFR-age association have 
varied widely,47-55 probably because of differences between the study populations. In potential 
living kidney donors, point estimates between -0.5 and -0.9 mL/min/1.73 m2/year have been 
found.51-53, 56-58  
If adjustment for health status had eliminated the GFR-age association, this would have 
supported the hypothesis that poor health fully accounts for the finding of lower mean GFR in 
old age.5 It is noteworthy that the SD of GFR did not increase with age in healthy persons as 
would be expected if a subset of this group had unrecognized kidney disease while others 
aged with preserved GFR. If even a minority of exceptionally healthy individuals aged with 
preserved rather than lower GFR, one would expect no or only a weak age association for the 
97.5th percentile of the GFR distribution. Although the absence of these findings in the 
present study does not refute the hypothesis, it suggests that age or other factors may 
contribute to the association. A similar finding regarding the 95th percentile was observed in a 
study of potential living kidney donors by Chakkera et al.59 The results are also consistent 
with histologic findings in biopsies from living kidney donors, which indicate that nephron 
number is lower at older age even in apparently healthy persons, although the study by Denic 
et al. only included persons younger than 75 years and may not be representative of older 
healthy people in the general population.6  
The observation of a high proportion of persons with non-declining GFR in some longitudinal 
studies may be explained by a failure to use statistical methods that take measurement error 
into account.8, 10, 12, 60-62 This will overestimate the variability of the rate at which GFR 
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declines and the proportion of persons with non-declining GFR. Also, none of these studies 
used precise methods to measure GFR,8-15, 60-66 and, except for one small Swedish study,67 
they were not population-based.60, 61, 63-66 The Baltimore Longitudinal Study of Aging is often 
referred to as having found that one-third of a group of healthy persons experienced no 
decline in GFR. However, the study may have been biased by the use of creatinine clearance 
for assessing GFR and the inclusion of patients with diabetes in the healthy group.60 
Being unhealthy was associated with a slightly higher GFR in the regression model (Table 3), 
which indicates that mean GFR for unhealthy persons was higher than for healthy persons 
among the youngest participants (Figure 3). One explanation for this paradoxical finding may 
be the glomerular hyperfiltration associated with obesity, smoking, elevated blood pressure 
and other risk factors. 68-73 Previous longitudinal results from the RENIS cohort and Pima-
Indians in the U.S. have indicated that hyperfiltration is independently associated with a more 
rapid decline in GFR.74 
The GFR-age association was less negative in men than in women (Table 3). This finding was 
consistent across all three cohorts and in models adjusting for differences in health status 
between the sexes. Previous population-based studies,9, 12 small studies using measured GFR 
51, 52, 54, 75-77 and studies of persons with established CKD 62, 78-81 have yielded mixed results 
about sex differences in GFR-age associations, but most of them did not fully adjust for 
comorbidity and risk factors. Our findings may partly explain the higher prevalence of CKD 
in women than in men, but do not explain why more men than women initiate renal 
replacement therapy.82  However, the findings should be interpreted with caution because of 
the lack of longitudinal data. 
Statistically significant random effects demonstrated differences in mean GFR for men and in 
GFR-age associations across the three cohorts (Table S3). Selection bias relative to the source 
populations in the RENIS and AGES-Kidney cohorts seems unlikely because these cohorts 
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had high participation rates and estimated GFR similar to those who did not participate. 23, 25, 
26 The participation rate in BIS was lower, but comparisons with the source population 
indicate that the cohort was representative.28 The most probable explanation for the 
heterogeneity may be unmeasured confounders. Unmeasured morbidity, risk factors and 
medications are the most likely possibilities, but differences in genetic, epigenetic or 
environmental factors cannot be excluded, as e.g. the dietary intake of protein. There are also 
other indications of geographical variations in kidney disease within Europe. One study of 
CKD prevalence found that Norway had the lowest and North-Eastern Germany the highest 
prevalence,83 and that these differences could not be explained by variations in hypertension, 
diabetes or obesity.  
One method for defining reference intervals for physiologic or biochemical parameters is to 
take the 95th interpercentile range of their distribution in a population of healthy persons. For 
age-dependent parameters, it is almost impossible to find cohorts of sufficient size for the 
oldest age groups, which include very few truly healthy individuals. 7 Accordingly, most 
previous studies of reference intervals for GFR have included few individuals older than 70 
years and have made no distinction between healthy subjects and others.53, 84-86 By contrast, 
we used a statistical model to estimate the effects of disease and risk factors and to predict 
percentiles of GFR in healthy persons between age 50 and 95 years. Because we adjusted for 
the heterogeneity between the cohorts, the predictions represent an average of the 
observations in three different geographic regions. 
A comparison between classification of low GFR based on the 2.5th percentile for healthy 
persons in the present study and the currently accepted criterion for CKD stage 3 to 5 (GFR < 
60 mL/min/1.73 m2) shows that the criterion underestimates the prevalence of low GFR in 
women younger than 67.1 years and in men younger than 70.8 years and overestimates the 
prevalences at higher ages (Figure 3). However, this is the result of applying a low percentile 
and a rather strict definition of “healthy” to assess the effect of age on GFR under optimal 
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physiologic conditions. In addition to reference intervals for GFR in healthy persons, an 
optimal classification system for CKD should be based on the risk of adverse outcomes at 
different levels of GFR. Further research of GFR as a risk factor in old age is needed.87  
In clinical practice, eGFRcrea is the most commonly used method for assessing GFR. Similar 
to iohexol clearance, both the median and 97.5th percentile of eGFRcrea had negative 
associations with age (Figure 4). However, there were several differences between eGFRcrea 
and iohexol clearance when modeling their relationship with age (Table S6). A study of 
potential kidney donors also found differences between the 95th percentiles of eGFRcrea and 
measured GFR.59 This indicates that measured GFR should be used for establishing reference 
intervals for GFR. 
The principal strength of this study is that we used measured instead of estimated GFR and 
that the cohorts are population-based. To our knowledge, the three cohorts included in the 
study are the only ones in Europe with these characteristics. The number of included persons 
far exceeds that of previous studies using measured GFR, especially in the oldest age groups. 
Although the low number of healthy persons in the highest age groups may have limited the 
power of statistical tests for the interaction between age, health status and other variables, it 
seems unlikely that we have failed to include a significant number of very old healthy persons 
with preserved GFR that would have changed our conclusion. 
A consensus about an operational definition of “healthy” does not exist. Although it could 
have been made more stringent, we believe that the definition used in this investigation is 
very conservative and excludes most common conditions that affect GFR. One exception is 
that the definition does not explicitly include heart failure because this information was not 
available in BIS and RENIS. However, we believe that the inclusion of other cardiovascular 
disease and medications as indicators of heart failure ensured that very few of these patients 
were misclassified as healthy (see Methods). Another possible limitation of the definition is 
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that it does not explicitly exclude persons with specific types of kidney disease, or persons 
with CKD based on kidney damage other than albuminuria as ascertained by kidney imaging 
or urine sediment examination. However, the criteria excluding persons with albuminuria and 
hypertension will probably also exclude most of these persons. Therefore, we assume that this 
limitation had only a small impact on our estimates.  
The heterogeneity between the three cohorts is a reason for caution in applying the results to 
other populations. We cannot exclude a survivor bias in the estimates of the GFR distribution, 
especially in the older age groups. However, this would support rather than weaken our 
conclusion of a lower GFR in older healthy persons. Due to the cross-sectional design of our 
study, the GFR-age associations apply at the population level, whereas the rates of change at 
the individual level could not be estimated. In principle, GFR-age associations observed over 
time in follow-up of individuals may differ from those observed across cohorts of individuals 
at different ages.88 However, even allowing for great variation and possible non-linear 
individual GFR trajectories, the finding that the 2.5th percentile in healthy 50 year old persons 
is similar to the 97.5th percentile in healthy 95 year old (Figure 3) suggests that ageing with 
preserved GFR across this age span must be very uncommon. Although difficult to perform, 
longitudinal studies of GFR decline would be of value to confirm these findings at the 
individual level. Another limitation was the difference between the cohorts regarding 
inclusion of subjects and available data on morbidity and risk factors. Statistical methods have 
been used to adjust for these differences.  
We conclude that there is a negative linear GFR-age association in healthy people aged 
between 50 and 95 years, and an even more negative association for people with chronic 
diseases and CKD risk factors. Although it can only conclusively be demonstrated in 
longitudinal studies with repeated GFR measurements in the same individuals, this finding 
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Number of participants, n (%) 1622 (100.0) 1324 (100.0) 547 (100.0) 716 (100.0)
Age (SD), years 58.1 (3.8) 63.6 (4.0) 78.4 (6.2) 80.3 (4.1)
Male sex, n (%) 797 (49.1) 657 (49.6) 311 (56.9) 317 (44.3)
Body weight (SD), kg 79.7 (14.4) 79.4 (14.3) 77.3 (14.0) 77.1 (14.1)
Height (SD), cm 170.6 (8.7) 170.6 (8.7) 166.2 (8.5) 167.7 (9.4)
Body mass index (SD), kg/m2 27.3 (4.0) 27.2 (4.1) 27.9 (4.3) 27.4 (4.3)
Body surface area (SD), m2 1.9 (0.2) 1.9 (0.2) 1.9 (0.2) 1.9 (0.2)
Cardiovascular disease
Myocardial infarction, n (%) 1 (0.1) 18 (1.4) 83 (15.2) 89 (12.4)
Myocardial revascularization, n (%) 5 (0.3) 26 (2.0) 93 (17.0) 113 (15.8)
Angina pectoris, n (%) 2 (0.1) 12 (0.9) 56 (10.2) 60 (8.4)
Stroke, n (%) 3 (0.2) 24 (1.8) 42 (7.7) 53 (7.4)
Diabetes, n (%) 19 (1.2) 42 (3.2) 136 (24.9) 81 (11.3)
Cancer, n (%) 76 (4.7) 120 (9.1) 123 (22.5) 134 (18.7)
Hypertensionb, n (%) 692 (42.7) 693 (52.3) 503 (92.0) 623 (87.0)
Systolic blood pressure (SD), mmHg 129.7 (17.6) 130.7 (17.0) 144.9 (21.5) 142.3 (20.3)
Diastolic blood pressure (SD), mmHg 83.4 (9.8) 81.9 (9.3) 82.3 (13.0) 69.6 (10.7)
Antihypertensive medication, n (%) 298 (18.4) 420 (31.7) 425 (77.7) 524 (73.2)
Digoxin or digitoxin, n (%) 1 (0.1) 6 (0.5) 18 (3.3) 24 (3.4)
Lipid lowering medication, n (%) 106 (6.5) 232 (17.5) 202 (36.9) 287 (40.1)
Anti-diabetic medication, n (%) 0 (0.0) 11 (0.8) 99 (18.1) 44 (6.1)
Smoking
Never, n (%) 503 (31.0) 432 (32.6) 263 (48.1) 295 (41.2)
Current, n (%) 344 (21.2) 177 (13.4) 32 (5.9) 42 (5.9)
Previous, n (%) 775 (47.8) 715 (54.0) 252 (46.1) 379 (52.9)
Absolute GFR (SD), mL/min 104.0 (20.1) 98.5 (19.8) 64.8 (19.2) 66.7 (19.4)
Body surface area-indexed GFR (SD), mL/min/ 1.73m2 94.0 (14.4) 89.1 (14.5) 60.5 (16.3) 61.9 (16.6)
CKDEPI estimate of GFR based on creatinine (SD), mL/min/ 1.73m3 94.9 (9.5) 88.2 (10.5) 68.8 (17.1) 65.5 (17.1)
Urinary albumin-to-creatinine ratio ≥ 30.0 mg/g, n (%) 24 (1.5) 26 (2.0) 126 (23.0) 110 (15.4)
Urinary albumin-to-creatinine ratio ≥ 300.0 mg/g, n (%) 1 (0.1) 2 (0.2) 19 (3.5) 15 (2.1)
Data are shown as mean (standard deviation) or n (percent).
aRENIS-T6 and RENIS-FU are the baseline and follow-up examinations of the RENIS cohort.
bOffice systolic blood pressure ≥ 140 mm Hg, office diastolic blood pressure ≥ 90 mm Hg, or the use of antihypertensive medications.
Abbreviations: RENIS-T6, Renal Iohexol Clearance in Tromsø 6;RENIS-FU, the Renal Iohexol-clearance Survey Follow-up Study; BIS, Berlin Initiative Study; AGES-Kidney, Age, 
Gene/Environment Susceptibility - Kidney Study; GFR, glomerular filtration rate; SD, standard deviation; CKDEPI, Chronic Kidney Disease Epidemiology Collaboration.
Table 1. Characteristics of the population-based cohorts








Unhealthy Healthya Unhealthy Healthy Unhealthy Healthy Unhealthy Healthy
RENIS-T6b 1109 513 94.2 93.1 65.6 63.0 123.1 118.9
RENIS-FUb 964 360 89.2 90.1 57.5 66.5 117.5 115.3
BIS 529 18 60.4 69.8c 29.7 44.2 88.7 96.2
AGES-Kidney 672 44 62.5 72.4c 26.2 42.4 90.5 98.4
Total 3274 935 82.6 90.8 34.0 59.7 117.8 118.0
c P<0.05 for difference between "unhealthy" and "healthy" category in the BIS and AGES-Kidney cohorts.
Abbreviations: RENIS-T6, Renal Iohexol Clearance in Tromsø 6;RENIS-FU, the Renal Iohexol-clearance Survey Follow-up Study; BIS, Berlin 
Initiative Study; AGES-Kidney, Age, Gene/Environment Susceptibility - Kidney Study; GFR, glomerular filtration rate .
bRENIS-T6 and RENIS-FU are the baseline and follow-up examinations of the same cohort.
Table 2. GFR (mL/min/1.73m2) according to health status 
of participants in the population-based cohorts.
Number of participants Median 2.5th percentile 97.5th percentile
a"Healthy" defined as no cardiovascular disease, cancer, diabetes, hypertension, smoking, lipid-lowering medication or digoxin, as well as body 
mass index <30 kg m-2 and urinary albumin-to-creatinine ratio < 30 mg g-1.
39 
 
   
Effect of independent variables on mean GFR
Variable β P-value
Unhealthy 50-year-old female (intercept) 98.91 97.43 to 100.39 <0.001
Age, per year -1.22 -1.43 to -1.02 <0.001
Healthy (yes/no)a -3.25 -4.86 to -1.63 <0.001
Male sex -0.82 -8.54 to 6.90 0.84
Interaction between age and being healthya 0.30 0.18 to 0.43 <0.001
Interaction between age and male sex 0.20 0.06 to 0.34 0.005
Effect of independent variables on the standard deviation of GFR
Variable β P-value
Unhealthy 50-year-old female (intercept) 12.40 10.53 to 14.61 <0.001
Percent change associated with each independent variable
Age, per year -0.1 % -0.6 % to 0.3 % 0.52
Healthy (yes/no)a -18.6 % -23.9 % to -13.0 % <0.001
Male sex 1.4 % -3.5 % to 6.6 % 0.59
a"Healthy" defined as no cardiovascular disease, cancer, diabetes, hypertension, smoking, lipid-lowering medication or digoxin, as well as 
body mass index <30 kg m-2 and urinary albumin-to-creatinine ratio < 30 mg/g.
GFR measured in mL/min/1.73 m2. Model adjusted for random cohort effects and for random intercepts for each participant, see 
supplementary Table S3 for random effect results.
Table 3. General additive mixed model analysis of GFR mean and standard deviation in 
three population-based cohorts. Fixed effects of health status, age and sex.
95% confidence interval
95% confidence interval
Abbreviations: RENIS, Renal Iohexol Clearance Survey; BIS, Berlin Initiative Study; AGES-Kidney, Age, Gene/Environment Susceptibility - 








Table 4. Predicted percentiles of GFR (mL/min/1.73 m2) for healthy women and men according to age groupa.
50 to 54 226 93.4 73.7 113.1 217 93.0 73.1 113.0
55 to 59 405 88.8 69.2 108.3 423 89.4 69.6 109.3
60 to 64 566 84.2 64.7 103.6 521 85.8 66.1 105.5
65 to 69 296 79.6 60.3 98.9 293 82.2 62.7 101.8
70 to 74 129 75.0 55.8 94.1 102 78.6 59.2 98.0
75 to 79 253 70.4 51.4 89.4 225 75.0 55.7 94.3
80 to 84 164 65.8 46.9 84.7 188 71.4 52.2 90.6
85 to 89 68 61.2 42.4 79.9 79 67.8 48.8 86.8
20 56.6 38.0 75.2 34 64.2 45.3 83.1
aEstimates corresponding to Figure 3.
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Figure 1. Inclusion of participants from RENIS-T6 (Renal Iohexol Clearance Survey in 
Tromsø 6), RENIS-FU (RENIS Follow-up Study), BIS (Berlin Initiative Study) and AGES-
Kidney (Age, Gene/Environment Susceptibility - Kidney Study) in the meta-analysis. The 
dashed arrow from RENIS-T6 to RENIS-FU indicates the repeated measurements of GFR in 
the RENIS cohort after a mean follow-up of 5.6 years. 
Figure 2. Body surface area-indexed GFR measured as plasma iohexol-clearance and plotted 
against age in the RENIS, BIS and AGES-Kidney cohorts (n=4209). The marker colors 
indicate cohort membership. Filled circles indicate measurements in healthy persons and 
crosses in unhealthy persons. Measurements for both the baseline (RENIS-T6) and the follow-
up examinations (RENIS-FU) of the same persons in the RENIS cohort are shown. The red 
and green curves represent unadjusted LOESS (locally estimated scatterplot smoothing) fits to 
measurements in unhealthy and healthy persons, respectively. 
Figure 3. Predicted median (bold black line), 2.5th and 97.5th percentiles (dashed black lines) 
as a function of age for healthy women (upper panel) and men (lower panel). The predicted 
median (gray line) and 95% interpercentile intervals (dark grey band) are shown for persons 
classified as unhealthy for comparison. The grey dashed line indicates the 60 mL/min/1.73 m2 
level 
Figure 4. Predicted medians (bold lines), 2.5th and 97.5th percentiles (dashed lines) of iohexol 
clearance (black) and eGFR based on creatinine (red) as functions of age for healthy women 
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The generalized additive regression model for location, scale and shape 
 
In ordinary regression analyses, the distribution of the dependent variable is commonly 
assumed to be normal conditional on the independent variables.  The mean of this distribution 
is estimated as a function of the independent variables, whereas its variance is assumed to be 
constant. However, in many real-life situations the variance may also be a function of the 
independent variables, and the distribution of the dependent variable may exhibit both 
skewness and kurtosis. In a generalized additive regression model for location, scale and 
shape (GAMLSS),1, 2  the parameters describing all these properties of the distribution of the 
dependent variable (the variance, skewness and kurtosis) can be estimated as separate 
functions of the independent variables. These functions may be non-linear and are often 
modeled as splines of the independent variables. 
The GAMLSS provides great flexibility in modeling population data, and percentiles of the 
conditional distribution of the dependent variable can be estimated to calculate reference 
intervals for e.g. age-dependent variables. The WHO has recommended this statistical method 
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Table S1. Missing data in RENIS-T6, RENIS-FU, BIS and AGES-Kidney.  
Table S1. Missing data in RENIS-T6, RENIS-FU, BIS and AGES-Kidney.
Number of participants
Age (years) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Male sex 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Body weight (kg) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Height (cm) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Body mass index (kg/m2) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Body surface area (m2) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Urinary albumin-to-creatinine ratio (mg/g) 5 (0.3 %) 0 (0.0 %) 6 (1.1 %) 3 (0.4 %)
Smoking 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 54 (6.7 %)
Myocardial infarction 0 (0.0 %) 0 (0.0 %) 8 (1.4 %) 0 (0.0 %)
Myocardial revascularization 0 (0.0 %) 0 (0.0 %) 6 (1.1 %) 0 (0.0 %)
Angina pectoris 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Stroke 0 (0.0 %) 0 (0.0 %) 5 (0.9 %) 0 (0.0 %)
Diabetes 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Cancer 0 (0.0 %) 0 (0.0 %) 2 (0.4 %) 0 (0.0 %)
Systolic blood pressure (mmHg) 0 (0.0 %) 0 (0.0 %) 1 (0.2 %) 2 (0.2 %)
Diastolic blood pressure (mmHg) 0 (0.0 %) 0 (0.0 %) 1 (0.2 %) 2 (0.2 %)
Antihypertensive medication 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 31 (3.9 %)
Digoxin or digitoxin 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 31 (3.9 %)
Lipid lowering medication 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 31 (3.9 %)
Anti-diabetic medication 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 31 (3.9 %)
Absolute GFR (mL min-1) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Participants without missing data 1622 (99.7 %) 1324 (100.0 %) 547 (96.0 %) 716 (88.9 %)
Data are shown as n(percent).
Abbreviations: RENIS-T6, Renal Iohexol Clearance in Tromsø 6;RENIS-FU Study, the Renal Iohexol-clearance Survey Follow-up Study; BIS, Berlin Initiative Study; AGES-
Kidney, Age, Gene/Environment Susceptibility - Kidney Study; GFR, glomerular filtration rate .
RENIS-T6 RENIS-Follow Up BIS AGES-Kidney
1627 1324 570 805
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Table S2. Characteristics of the study population according to health status 
Number of observations, n (%) 3274 (100.0) 935 (100.0)
Age (SD), years 67.8 (10.2) 60.8 (6.6)
Male sex, n (%) 1673 (51.1) 409 (43.7)
Body weight (SD), kg 80.4 (14.8) 73.4 (10.8)
Height (SD), cm 169.3 (9.0) 170.3 (8.7)
Body mass index (SD), kg/m2 28.0 (4.3) 25.2 (2.5)
Body surface area (SD), m2 1.9 (0.2) 1.8 (0.2)
Cardiovascular disease
Myocardial infarction, n (%) 191 (5.9) 0 (0.0)
Myocardial revascularization, n (%) 237 (7.3) 0 (0.0)
Angina pectoris, n (%) 130 (4.0) 0 (0.0)
Stroke, n (%) 122 (3.8) 0 (0.0)
Diabetes, n (%) 278 (8.5) 0 (0.0)
Cancer, n (%) 453 (13.8) 0 (0.0)
Hypertensionb, n (%) 2511 (76.7) 0 (0.0)
Systolic blood pressure (SD), mmHg 138.1 (19.6) 120.2 (10.4)
Diastolic blood pressure (SD), mmHg 81.4 (12.2) 77.3 (7.4)
Antihypertensive medication, n (%) 1667 (50.9) 0 (0.0)
Digoxin or digitoxin, n (%) 49 (1.5) 0 (0.0)
Lipid lowering medication, n (%) 827 (25.3) 0 (0.0)
Anti-diabetic medication, n (%) 154 (4.7) 0 (0.0)
Smoking
Never, n (%) 1109 (33.9) 384 (41.1)
Current, n (%) 595 (18.2) 0 (0.0)
Previous, n (%) 1570 (48.0) 551 (58.9)
Absolute GFR (SD), mL/min 89.1 (27.1) 96.9 (18.9)
Body surface indexed GFR (SD), mL/min/ 1.73m2 80.3 (21.6) 90.6 (14.4)
CKDEPI estimate of GFR based on creatinine (SD), mL/min/ 1.73m3 82.4 (18.2) 91.4 (10.6)
Urinary albumin-creatinine ratio ≥ 30.0 mg/g, n (%) 286 (8.7) 0 (0.0)
Urinary albumin-to-creatinine ratio ≥ 300.0 mg/g, n (%) 37 (1.1 %) 0 (0.0 %)
Data are shown as mean (standard deviation) or n (percent).
cOffice systolic blood pressure ≥ 140 mm Hg, office diastolic blood pressure ≥ 90 mm Hg, or the use of antihypertensive medications.
Table S2. Characteristics of the study populationa 
according to health status
Unhealthy Healthyb
Abbreviation: GFR, glomerular filtration rate; SD, standard deviation; CKDEPI, Chronic Kidney Disease Epidemiology Collaboratio.
b"Healthy" defined as no cardiovascular disease, cancer, diabetes, hypertension, smoking, lipid-lowering medication or digoxin, as well 
as body mass index <30 kg m-2 and urinary albumin-to-creatinine ratio < 30 mg g-1.
aThe study  population comprises both the baseline and follow-up examinations of the RENIS cohort (RENIS-T6 and RENIS-FU), which 
means that the standard deviations in the table should be interpreted with caution. 
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Table S3. General additive mixed model analysis of GFR mean and standard deviation 
in three population-based cohorts. Fixed and random effects.  
Fixed effects
Effect of independent variables on mean GFR
Variable β P-value
Unhealthy 50-year-old female (intercept) 98.91 97.43 to 100.39 <0.001
Age, per year -1.22 -1.43 to -1.02 <0.001
Healthy (yes/no)a -3.25 -4.86 to -1.63 <0.001
Male sex -0.82 -8.54 to 6.90 0.84
Interaction between age and being healthya 0.30 0.18 to 0.43 <0.001
Interaction between age and male sex 0.20 0.06 to 0.34 0.005
Effect of independent variables on the standard deviation of GFR
Variable β P-value
Unhealthy 50-year-old female (intercept) 12.40 10.53 to 14.61 <0.001
Percent change associated with each independent variable
Age, per year -0.1 % -0.6 % to 0.3 % 0.52
Healthy (yes/no)a -18.6 % -23.9 % to -13.0 % <0.001
Male sex 1.4 % -3.5 % to 6.6 % 0.59
Random effects
Effect of independent variables on mean GFR
Variable Estimate P-value
Cohort effect for males
RENISb 6.59 -0.67 to 13.85 0.07
BISb -4.86 -12.05 to 2.34 0.19
AGES-Kidneyb -1.73 -8.95 to 5.48 0.64
Standard deviation of random effect 6.16 2.19 to 17.28 0.003
Interaction between cohort effect and age
RENISb 0.19 -0.01 to 0.39 0.06
BISb -0.13 -0.33 to 0.07 0.20
AGES-Kidneyb -0.06 -0.26 to 0.13 0.54
Standard deviation of random effect 0.17 0.06 to 0.47 0.03
Random intercept, standard deviation 5.09 4.80 to 5.39 <0.001
Effect of independent variables on the standard deviation of GFR
Variable Estimate P-value
Cohort effect, percent change associated with each independent variable
RENISb -15 % -26 % to -2.1 % 0.02
BISb 5.0 % -8.4 % to 20 % 0.48
AGES-Kidneyb 12 % -2 % to 28 % 0.11
Standard deviation of random effect 12 % 3.7 % to 41 % <0.001
bBest linear unbiased predictions of effects.
Table S3. General additive mixed model analysis of GFR mean and standard deviation 
in three population-based cohorts. Fixed and random effects.
95% confidence interval
a"Healthy" defined as no cardiovascular disease, cancer, diabetes, hypertension, smoking, lipid-lowering medication or digoxin, as well as 
body mass index <30 kg m-2 and urinary albumin-to-creatinine ratio < 30 mg/g.
95% confidence interval
Abbreviations: RENIS, Renal Iohexol Clearance Survey; BIS, Berlin Initiative Study; AGES-Kidney, Age, Gene/Environment Susceptibility - 
Kidney Study; GFR, glomerular filtration rate.
95% confidence interval
95% confidence interval
GFR measured in mL/min/1.73 m2. The fixed effect part of this table is identical to Table 3 in the main article.
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Table S4. General additive mixed model analysis of GFR mean and standard deviation 
in three population-based cohorts. Fixed cohort effects. 
Effect of independent variables on mean GFR
Variable β P-value
Unhealthy 50-year-old female (intercept) 98.87 97.37 to 100.37 <0.001
Age, per year -1.22 -1.30 to -1.14 <0.001
Healthy (yes/no)a -3.22 -4.84 to -1.59 <0.001
Male sex -0.96 -4.36 to 2.44 0.58
Interaction between age and being healthya 0.30 0.18 to 0.42 <0.001
Interaction between age and male sex 0.20 0.06 to 0.34 0.004
Male in the RENIS cohort 6.69 4.60 to 8.78 <0.001
Male in the BIS cohort -4.92 -6.77 to -3.08 <0.001
Male in the AGES-Kidney cohort -1.77 -3.70 to 0.17 0.07
Age, per year, in the RENIS cohort 0.19 0.14 to 0.25 <0.001
Age, per year, in the BIS cohort -0.13 -0.18 to -0.08 <0.001
Age, per year, in the AGES-Kidney cohort -0.06 -0.11 to -0.02 0.006
Effect of independent variables on the standard deviation of GFR
Variable β P-value
Unhealthy 50-year-old female (intercept) 12.98 11.68 to 14.44 <0.001
Percent change associated with each independent variable
Age, per year -0.3 % -0.8 % to 0.1 % 0.14
Healthy (yes/no)a -18 % -24 % to -13 % <0.001
Male sex 1.5 % -3.4 % to 6.7 % 0.56
RENIS cohort -18 % -23 % to -12 % <0.001
BIS cohort 6 % 1 % to 12 % 0.02
AGES-Kidney cohort 14 % 8 % to 21 % <0.001
The standard deviation of the random intercept in this model was 5.09 (95% confidence interval 4.81 to 5.39).
GFR measured in mL/min/1.73 m2. This model is identical to the model in Table S3, but uses fixed instead of random cohort effects.
a"Healthy" defined as no cardiovascular disease, cancer, diabetes, hypertension, smoking, lipid-lowering medication or digoxin, as well as 
body mass index <30 kg m-2 and urinary albumin-to-creatinine ratio < 30 mg/g.
Table S4. General additive mixed model analysis of GFR mean and standard deviation 
in three population-based cohorts. Fixed cohort effects.
95% confidence interval
95% confidence interval
Abbreviations: RENIS, Renal Iohexol Clearance Survey; BIS, Berlin Initiative Study; AGES-Kidney, Age, Gene/Environment Susceptibility - 
Kidney Study; GFR, glomerular filtration rate.
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Table S5. Predicted percentiles of GFR (mL/min/1.73 m2) for healthy women and men 
according to age group.  
Table S5. Predicted percentiles of GFR (mL/min/1.73 m2) for healthy women and men according to age groupa.
10th percentile 25th percentile 75th percentile 90th percentile 10th percentile 25th percentile 75th percentile 90th percentile
50 to 54 80.5 86.6 100.2 106.3 80.0 86.2 99.9 106.1
55 to 59 76.0 82.0 95.5 101.6 76.5 82.6 96.3 102.4
60 to 64 71.5 77.5 90.9 96.9 72.9 79.0 92.6 98.7
65 to 69 67.0 72.9 86.2 92.2 69.4 75.5 89.0 95.0
70 to 74 62.4 68.4 81.6 87.5 65.9 71.9 85.3 91.3
75 to 79 57.9 63.8 76.9 82.8 62.4 68.4 81.6 87.6
80 to 84 53.4 59.3 72.3 78.1 58.9 64.8 78.0 83.9
85 to 89 48.9 54.7 67.6 73.5 55.4 61.2 74.3 80.2
44.4 50.2 63.0 68.8 51.8 57.7 70.7 76.5






Table S6. General additive mixed model analysis of creatinine-based eGFR mean and 
standard deviation in three population-based cohorts. Fixed and random effects.  
Fixed effects
Effect of independent variables on mean eGFR
Variable β P-value
Unhealthy 50-year-old female (intercept) 101.92 100.91 to 102.92 <0.001
Age, per year -1.13 -1.29 to -0.97 <0.001
Healthy (yes/no)a -1.87 -3.02 to -0.71 0.002
Male sex 0.83 -0.22 to 1.87 0.12
Interaction between age and being healthya 0.19 0.10 to 0.29 <0.001
Interaction between age and male sex 0.00 -0.07 to 0.08 0.905
Effect of independent variables on the standard deviation of eGFR
Variable β P-value
Unhealthy 50-year-old female (intercept) 10.28 7.45 to 14.20 <0.001
Percent change associated with each independent variable
Age, per year 1.0 % 0.5 % to 1.4 % <0.001
Healthy (yes/no)a -21.5 % -26.7 % to -15.9 % <0.001
Male sex -15.0 % -19.3 % to -10.5 % <0.001
Random effects
Effect of independent variables on mean eGFR
Variable Estimate P-value
Cohort effect for males
RENISb 0.00 -0.02 to 0.02 0.99
BISb 0.00 -0.02 to 0.02 0.99
AGES-Kidneyb 0.00 -0.02 to 0.02 1.00
Standard deviation of random effect 0.01 0.01 to 0.01 0.06
Interaction between cohort effect and age
RENISb 0.14 -0.01 to 0.29 0.07
BISb -0.05 -0.20 to 0.10 0.49
AGES-Kidneyb -0.09 -0.24 to 0.06 0.25
Standard deviation of random effect 0.13 0.05 to 0.35 <0.001
Random intercept, standard deviation 3.56 3.40 to 3.72 <0.001
Effect of independent variables on the standard deviation of eGFR
Variable Estimate P-value
Cohort effect, percent change associated with each independent variable
RENISb -31 % -50 % to -6.4 % 0.02
BISb 22.0 % -10.4 % to 66 % 0.21
AGES-Kidneyb 20 % -12 % to 63 % 0.26
Standard deviation of random effect 31 % 10.4 % to 108 % <0.001
bBest linear unbiased predictions of effects.
eGFR measured in mL/min/1.73 m2.
a"Healthy" defined as no cardiovascular disease, cancer, diabetes, hypertension, smoking, lipid-lowering medication or digoxin, as well as 
body mass index <30 kg m-2 and urinary albumin-to-creatinine ratio < 30 mg/g.
Table S6. General additive mixed model analysis of creatinine-based eGFR mean and 





Abbreviations: RENIS, Renal Iohexol Clearance Survey; BIS, Berlin Initiative Study; AGES-Kidney, Age, Gene/Environment Susceptibility - 





Figure S1. Histogram showing the residuals for the final GAMLSS model of GFR 
corresponding to Table 3 in the main article. 
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